ArticleBiomarker research2023

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies.

Xiuwen Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.